

SNLong Term Care Facility Component—Annual Facility Survey

, L À	Netw		ĸ	
	Page	1	of	6

Instructions for this form can be accessed: <u>https://www.cdc.gc</u>	v/nhsn/forms/instr/57.137-toi-annual-facility-survey.pdf				
*Required for saving	Tracking #:				
Facility ID:	*Survey Year:				
*National Provider ID:	State Provider #:				
Facility Characteristics					
*Ownership (check one):					
□ For profit □ Not for profit, including church	\Box Government (not VA) \Box Veterans Affairs				
*Certification (check one):					
Dual Medicare/Medicaid Dedicare only	Medicaid only State only				
*Affiliation (check one): 🗌 Independent, free-standing	Independent, continuing care retirement community				
	, attached 🛛 Hospital system, free-standing				
In the previous calendar year: *Average daily census:					
*Total number of short-stay residents: Averag *Total number of long-stay residents: Averag	e length of stay for short-stay residents: e length of stay for long-stay residents:				
*Total number of new admissions:					
*Number of Beds: *Number of Pediatric Beds (age <21): *Indicate which of the following primary service types are provided by your facility. On the day of this survey, indicate the number of residents receiving those services (list only one service type per resident, i.e. total should sum to resident census on day of survey completion):					
Primary Service Type	Service provided? Number of residents				
a. Long-term general nursing:					
b. Long-term dementia:					
c. Skilled nursing/Short-term (subacute) rehabilitation:					
d. Long-term psychiatric (non-dementia):					
e. Ventilator:					
f. Bariatric:					
g. Hospice/Palliative:					
h. Other:					
Assurance of Confidentiality: The voluntarily provided information obtained in this survei collected with a guarantee that it will be held in strict confidence, will be used only for the consent of the individual, or the institution in accordance with Sections 304, 306 and 308	purposes stated, and will not otherwise be disclosed or released without the				

Public reporting burden of this collection of information is estimated to average 135 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666).

CDC 57.137 (Front) Rev 13.0 Release- January 2025



Facility Microbiology Laboratory P	ractices			
*1. Does your facility have its own lab		microbiology/antir	nicrobial susceptibility te	sting?
🗆 Yes 🛛 No				
If No, where is your facility's a	ntimicrobial susceptib	ility testing perform	ed? (check one)	
□ Affiliated medica	l center, within same l	health system	\Box Medical center, co	ontracted locally
\Box Commercial refe	rral laboratory			
*2. Indicate whether your facility scre (MDROs): (check all that apply)	ens new admissions f	or any of the follow	ving multidrug-resistant o	irganisms
\Box We do not screen new adm	issions for MDROs			
Methicillin-resistant Staphyl If checked, indicate the sp	•		all that apply)	
\Box Nasal swabs	\Box Wound swabs	□ Sputum	\Box Other skin site	
□ Vancomycin-resistant Enter	rococcus (VRE)	·		
If checked, indicate the sp	. ,	r screening: (check	all that apply)	
\Box Rectal swabs	\Box Wound swabs	Urine		
Multidrug-resistant gram-ne resistant Acinetobacter, etc If checked, indicate the sp	.)	·		eae; multidrug-
\Box Rectal swabs	\Box Wound swabs	□ Sputum	Urine	
Candida Auris (C.Auris) If checked, indicate the sp	becimen types sent for	r screening: (check	all that apply)	
□ Skin (axilla/groin)		□ Nares [Other site	
3. What is the primary testing metho where your facility's testing is per			facility's laboratory or th	e outside laboratory
🗌 Enzyme immunoassay (EIA)	for toxin	🗌 GDH plu:	s NAAT (2-step algorithm	ו)
\Box Cell cytotoxicity neutralization	assay	-	GDH plus EIA for toxin, followed by NAAT for discrepant results	
Nucleic acid amplification tes LAMP)	t (NAAT) (e.g., PCR,	Culture (toxins)	\Box Culture (<i>C. difficile</i> culture followed by detection of	
🗌 NAAT plus EIA, if NAAT posi	tive (2-step algorithm)	Other (specify):		
Glutamate dehydrogenase (C toxin (2-step algorithm)	GDH) antigen plus EIA	for		
("Other" should not be used to name spe methods can be categorized accurately b Instructions for this form, or conduct a se	y selecting from the opt	ions provided. Pleas	e ask your laboratory, refer	
*4. Does your laboratory provide a re identified in cultures sent from yo			ic resistance seen in con	nmon organisms
🗆 Yes 🛛 No				
If Yes, how often is this summar	y report or antibiograr	n provided to your	facility? (check one)	
\Box Once a year	Every 2 years	□ Other (spec	cify):	



	Long Term Care Facility Component—Annual Facility Survey
Infecti	on Prevention and Control Practices
	addition to the Infection Preventionist (IP) role, how many other roles is the IP responsible for? Select all that apply: Director of Nursing
	Assisted Director of Nursing
	Floor Nurse (clinical)
	Administrator
	Other
	at formal training has your Infection Preventionist received? Select all that apply: None
	Infection Prevention Training Course through CDC
	Infection Prevention Training Course through State Health Department
	Other
*7. Wh	at certification has your infection preventionist obtained? Select all that apply:
	None
	Certification in Infection Control (CIC)
	Long-Term Care Certification in Infection Prevention (LTC-CIP)
	Other
	w many times in the past year have you had to find a new employee to take over the Infection Preventionist (IP) n other words, how many times has this position "turned over"? (check one)
	Did not turn over the IP role in the past year
	Once
	Twice
	Three
	Four or more
*9. Tota facility:	al infection preventionist hours per week dedicated to infection prevention and control activity in
	Total hours per week performing surveillance:
	it a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with RSA? (check one)
	Yes, all infected and colonized residents with MRSA



 A M M A Matter are affer y Network Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device) No
*11. Is it a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with VRE? (check one)
\Box Yes, all infected and colonized residents with VRE
 Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device) No
*12. Is it a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with CRE? (check one)
\Box Yes, all infected and colonized residents with CRE
Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device)
□ No
*13. Is it a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with ESBL-producing or extended spectrum cephalosporin resistant Enterobacteriaceae? (check one)
\Box Yes, all infected and colonized residents with ESBL
Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device)
*14. When a resident colonized or infected with an MDRO is transferred to another facility, does your facility communicate the resident's MDRO status to the receiving facility at the time of transfer?
Continued >>



Infection Prevention and Control Practices (continued)		
*15. Among residents with an MDRO admitted to your facility from other healthcare facilities, what percentage of the time does your facility receive information from the transferring facility about resident's MDRO status?		%
Antibiotic Stewardship Practices		
*16. Are there one or more individuals responsible for the impact of activities to improve use of antimicrobials at your facility?	□ Yes	🗆 No
If Yes, what is the position of the individual(s)? (select all that apply)		
□ Medical director □ Director of Nursing □ Infection Preventio	nist	
Consultant Pharmacist		
*17. Does your facility have a policy that requires prescribers to document an indication for all antimicrobials in the medical record or during order entry?	□ Yes	□ No
If Yes, has adherence to the policy to document an indication been monitored?	□ Yes	🗌 No
*18. Does your facility provide treatment recommendations for common infections based on national guidelines to assist with antimicrobial decision making?	□ Yes	🗆 No
If Yes, has adherence to facility-specific treatment recommendations been monitored?	□ Yes	🗆 No
*19. Is there a formal procedure for performing a follow-up assessment 2-3 days after a new antimicrobial start to determine whether the antimicrobial is still indicated and appropriate (e.g. antibiotic time out)?	□ Yes	□ No
*20. Is there a formal procedure for reviewing courses of antimicrobial therapy and communicating with prescribers on antimicrobial selection, dosing, or duration of therapy (i.e., audit and feedback) at your facility?	□ Yes	□ No
*21. Does your facility have a system for tracking antimicrobial use? If yes, what is the source of the antimicrobial use report provided?	□ Yes	
Pharmacy services Electronic Health Records		
□ Manual reporting (i.e., facility infection control log) □ Other (please specify):		
*22. Has your facility provided education to clinicians and other facility staff on improving antimicrobial use in the past 12 months?	□ Yes	□ No
*23. Does your facility have a written statement of support from leadership that supports efforts to improve antimicrobial use?	□ Yes	□ No
	Cor	tinued >>



ation

Antibiotic Stewardship Prac	tices (continued)		
	d resistance data reviewed by mprovement committee meet		🗆 Yes 🛛
consultant pharmacist tra		imicrobial stewardship expertise ship, stewardship team at referr ultant)?	
Electronic Health Record U	tilization		
26. Indicate whether any of t	ne following are available in ϵ	an <u>electronic health record</u> (cheo	ck all that apply):
☐ Microbiology lab cu susceptibility result	ulture and antimicrobial s	\Box Medication orders	
\Box Medication adminis	stration record	\Box Resident vital signs	
Resident admission	n notes	\Box Resident progress notes	
□ Resident transfer c	r discharge notes	\Box None of the above	
27. Have you ever conducted	a facility risk assessment to i	dentify where <i>Legionella</i> and	
7. Have you ever conducted other opportunistic waterborne Burkholderia, Stenotrophomol pread in the facility water sys	a facility risk assessment to i e pathogens (e.g. <i>Pseudomol</i>	nas, Acinetobacter, cteria, and fungi) could grow and re)?	d 🗌 Yes 🗌 No
7. Have you ever conducted ther opportunistic waterborne Burkholderia, Stenotrophomol pread in the facility water sys	a facility risk assessment to i e pathogens (e.g. <i>Pseudomol</i> nas, nontuberculous mycobac stem (e.g., piping infrastructur	nas, Acinetobacter, cteria, and fungi) could grow and re)?	d 🗌 Yes 🗌 No
other opportunistic waterborne Burkholderia, Stenotrophomol spread in the facility water sys If Yes, when was the mos	a facility risk assessment to i e pathogens (e.g. <i>Pseudomol</i> nas, nontuberculous mycobac stem (e.g., piping infrastructur	nas, Acinetobacter, cteria, and fungi) could grow and re)? red? (Check one)	d 🗌 Yes 🗌 No
27. Have you ever conducted other opportunistic waterborne Burkholderia, Stenotrophomol opread in the facility water syst If Yes, when was the most □ ≤ 1 year ago □ > 3 years ago 28. Does your facility have a waransmission of Legionella and	a facility risk assessment to i e pathogens (e.g. <i>Pseudomol</i> nas, nontuberculous mycobac stem (e.g., piping infrastructur	nas, Acinetobacter, cteria, and fungi) could grow and re)? .ed? (Check one) □ >1 and ≤ 3 years ago o prevent the growth and rne pathogens?	d □ Yes □ No
27. Have you ever conducted other opportunistic waterborne Burkholderia, Stenotrophomol opread in the facility water syst If Yes, when was the most □ ≤ 1 year ago □ > 3 years ago 28. Does your facility have a waransmission of Legionella and	a facility risk assessment to i e pathogens (e.g. <i>Pseudomol</i> nas, nontuberculous mycobac stem (e.g., piping infrastructur st recent assessment conduct water management program t d other opportunistic waterboo	nas, Acinetobacter, cteria, and fungi) could grow and re)? 	u
 27. Have you ever conducted other opportunistic waterborned other opportunistic waterborned surkholderia, Stenotrophomol spread in the facility water system of Yes, when was the most of Yes, when was the most of 2 × 3 years ago 28. Does your facility have a water system of <i>Legionella</i> and <i>L</i>	a facility risk assessment to i e pathogens (e.g. <i>Pseudomol</i> nas, nontuberculous mycobac stem (e.g., piping infrastructur st recent assessment conduct water management program t d other opportunistic waterboo d on the team? (Check all tha D Nursing Leadership	nas, Acinetobacter, cteria, and fungi) could grow and re)? 	□ Yes □ No □ Facilities Manager/
 7. Have you ever conducted ther opportunistic waterborned surkholderia, Stenotrophomol pread in the facility water system of Yes, when was the most of Yes, when was the most of 2 ≤ 1 year ago 8. Does your facility have a water size of Yes, who is represented of Yes, who is represented of Yes, who is represented of Facility Administrator 	a facility risk assessment to i e pathogens (e.g. <i>Pseudomoi</i> nas, nontuberculous mycobad stem (e.g., piping infrastructur st recent assessment conduct water management program t d other opportunistic waterboo d on the team? (Check all tha D Nursing Leadership (e.g., DON or ADON)	nas, Acinetobacter, cteria, and fungi) could grow and re)? □ <1 and ≤ 3 years ago o prevent the growth and rne pathogens? tt apply) □ Consultant Risk/Quality	☐ Yes ☐ No ☐ Facilities Manager/ Engineer
 27. Have you ever conducted other opportunistic waterborned other opportunistic waterborned opportunistic water opportunistic waterborned opportunistic water opportunistic water opportunistic water opportunistic opportunis	a facility risk assessment to i e pathogens (e.g. <i>Pseudomol</i> nas, nontuberculous mycobad stem (e.g., piping infrastructur st recent assessment conduct water management program t d other opportunistic waterbook on the team? (Check all tha D Nursing Leadership (e.g., DON or ADON)	has, Acinetobacter, cteria, and fungi) could grow and re)? ed? (Check one) □ >1 and ≤ 3 years ago o prevent the growth and rne pathogens? tt apply) □ Consultant □ Risk/Quality Management Staff	□ Yes □ No □ Facilities Manager/ Engineer □ Medical Director

Continued >>



NHSN National Healting of 6 of 6	Long Term Care Facility Component—Annual Facility Survey					
le ourory network	Temperature	🗌 Yes	🗆 No			
	If Yes, do you have a plan for cor temperatures are not within acce your water management program	ptable limits as deterr	nined by	□ Yes	□ No	
	Heterotrophic plate counts	🗌 Yes	🗆 No			
	If Yes, do you have a plan for cor heterotrophic plate counts are no determined by your water manag	t within acceptable lir	nits as	□ Yes	□ No	
	Specific tests for Legionella	🗌 Yes	🗌 No			
	If Yes, do you have a plan for cor tests for <i>Legionella</i> are not within by your water management progr	acceptable limits as		□ Yes	□ No	